Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | Chief Operations Officer | June 09, 2025 | June 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date June 09, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,141 |
Reported balance
After 2025-06-09 transaction · row 1
1 source rowRow 1 · 2025-06-09 · Sale · Disposed 552 · Balance 250,141 F1: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2025 Filed Jun 11, 2025 21:05 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 552 | $0.62 | $343.34 |
DisclosureSEC source: 0001062993-25-011428 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,141 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| May 05, 2025 Filed May 7, 2025 20:38 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 1,024 | $0.55 | $563.20 |
DisclosureSEC source: 0001062993-25-008775 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,693 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:27 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-005289 · form4.xml · derivative · entry 3 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-03-11 F3 · derivative.exercise_date: The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 23:27 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005289 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,717 F2 · kind: Reflects the grant of RSUs. Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:27 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 2,359 | $0.62 | $1,450.79 |
DisclosureSEC source: 0001062993-25-005289 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,717 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 22:31 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 1,054 | $0.78 | $822.12 |
DisclosureSEC source: 0001062993-25-001756 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,076 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:59 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 1,033 | $1.23 | $1,267.49 |
DisclosureSEC source: 0001062993-24-018339 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,130 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:06 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 1,073 | $1.83 | $1,960.37 |
DisclosureSEC source: 0001062993-24-014585 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,163 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| May 03, 2024 Filed May 7, 2024 21:13 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 913 | $3.11 | $2,835.78 |
DisclosureSEC source: 0001062993-24-009573 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,236 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionStock Option (right to buy) · Derivative | 22,831 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · derivative · entry 6 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,655 Underlying: Common Stock · 22,831 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 22,831 | $5.14 | $117,342.21 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 4 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,149 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.48, inclusive. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionCommon Stock | 22,831 | $1.03 | $23,515.93 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 3 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:35 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 146,000 | $0.00 Strike: $5.32 | $0.00 |
DisclosureSEC source: 0001062993-24-006182 · form4.xml · derivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 146,000 shares Expires 2034-03-07 F2 · derivative.exercise_date: The option vests 25% on March 7, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 23:35 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-006182 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,149 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on March 7, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionStock Option (right to buy) · Derivative | 30,684 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · derivative · entry 5 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,486 Underlying: Common Stock · 30,684 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 30,684 | $4.96 | $152,339.92 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,149 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:29 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionCommon Stock | 30,684 | $1.03 | $31,604.52 |
DisclosureSEC source: 0001062993-24-006058 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionStock Option (right to buy) · Derivative | 485 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-24-003878 · form4.xml · derivative · entry 3 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,170 Underlying: Common Stock · 485 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 485 | $4.86 | $2,358.26 |
DisclosureSEC source: 0001062993-24-003878 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,149 F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $4.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:10 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | Exercise / conversionCommon Stock | 485 | $1.03 | $499.55 |
DisclosureSEC source: 0001062993-24-003878 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 22:21 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 1,784 | $4.49 | $8,004.81 |
DisclosureSEC source: 0001062993-24-002320 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,149 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 22:21 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | SaleCommon Stock | 2,035 | $3.84 | $7,816.44 |
DisclosureSEC source: 0001062993-24-002320 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,933 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · derivative · entry 4 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · derivative · entry 3 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,968 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,093 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:51 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001062993-22-001689 · form4.xml · derivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vests 25% on January 25, 2023, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.